Nevertheless, a gene therapy for RP has been approved, albeit exclusively for a limited subset of patients with the RPE65 gene mutation which represents approximately 0.3–1% of all RP cases, among almost 100 involved gene mutations. The gene discussed is RPE65; the disease is retinitis pigmentosa 1.